中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 8
Aug.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(8): 1639-1642

Large spontaneous splenorenal shunt embolization combined with anticoagulant therapy in treatment of portal vein thrombosis： A case report

DOI: 10.12449/JCH250825

  • Department of Gastroenterology and Hepatology，Laboratory of Gastrointestinal Cancer and Liver Disease，West China Hospital，Sichuan University，Chengdu 610041，China

Research funding:

The 1·3·5 Project for Disciplines of Excellence of West China Hospital, Sichuan University (ZYGD23031)

More Information
  • Corresponding author: YANG Li， yangli_hx@scu.edu.cn （ORCID： 0000-0003-3821-9342）
  • Received Date: 2024-11-10
  • Accepted Date: 2025-01-13
  • Published Date: 2025-08-25
    Abstract
  • Portal vein thrombosis （PVT） is a common and severe complication in patients with liver cirrhosis， and alterations in portal hemodynamics are closely associated with the development of PVT. The presence of large spontaneous splenorenal shunt （SSRS） may lead to reductions in portal vein perfusion and blood flow velocity， which may compromise the anticoagulant effect on PVT. This article reports the treatment strategies of SSRS embolization combined with anticoagulant therapy that help to achieve complete recanalization of the portal vein； however， high-quality clinical studies are still needed to further validate and support the effectiveness of this strategy.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    STINE JG, WANG J, SHAH PM, et al. Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study[J]. Liver Int, 2018, 38( 1): 94- 101. DOI: 10.1111/liv.13500.
    [2]
    SIMÓN-TALERO M, ROCCARINA D, MARTÍNEZ J, et al. Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis[J]. Gastroenterology, 2018, 154( 6): 1694- 1705. e 4. DOI: 10.1053/j.gastro.2018.01.028.
    [3]
    NARDELLI S, RIGGIO O, TURCO L, et al. Relevance of spontaneous portosystemic shunts detected with CT in patients with cirrhosis[J]. Radiology, 2021, 299( 1): 133- 140. DOI: 10.1148/radiol.2021203051.
    [4]
    KE Q, YU XP, WANG X, et al. Prevalence, clinical characteristics, and outcomes of spontaneous portosystemic shunt in patients with hepatitis B-related cirrhosis: A multicenter study from China[J]. Dig Liver Dis, 2023, 55( 10): 1382- 1390. DOI: 10.1016/j.dld.2023.04.012.
    [5]
    Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis(2020, Shanghai)[J]. J Clin Hepatol, 2020, 36( 12): 2667- 2674. DOI: 10.3969/j.issn.1001-5256.2020.12.007.

    中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年, 上海)[J]. 临床肝胆病杂志, 2020, 36( 12): 2667- 2674. DOI: 10.3969/j.issn.1001-5256.2020.12.007.
    [6]
    PAN JH, WANG L, GAO FB, et al. Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis[J]. Eur J Intern Med, 2022, 104: 21- 32. DOI: 10.1016/j.ejim.2022.05.032.
    [7]
    SENZOLO M, GARCIA-TSAO G, GARCÍA-PAGÁN JC. Current knowledge and management of portal vein thrombosis in cirrhosis[J]. J Hepatol, 2021, 75( 2): 442- 453. DOI: 10.1016/j.jhep.2021.04.029.
    [8]
    QI XS, de STEFANO V, LI HY, et al. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis of observational studies[J]. Eur J Intern Med, 2015, 26( 1): 23- 29. DOI: 10.1016/j.ejim.2014.12.002.
    [9]
    STINE JG, SHAH PM, CORNELLA SL, et al. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis[J]. World J Hepatol, 2015, 7( 27): 2774- 2780. DOI: 10.4254/wjh.v7.i27.2774.
    [10]
    LYU SC, HE Q. Research progress in perioperative management of portal vein thrombosis in liver transplantation[J]. Organ Transplant, 2024, 15( 1): 26- 32. DOI: 10.3969/j.issn.1674-7445.2023185.

    吕少诚, 贺强. 肝移植围手术期门静脉血栓管理的研究进展[J]. 器官移植, 2024, 15( 1): 26- 32. DOI: 10.3969/j.issn.1674-7445.2023185.
    [11]
    GUERRERO A, DEL CAMPO L, PISCAGLIA F, et al. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis[J]. J Hepatol, 2023, 79( 1): 69- 78. DOI: 10.1016/j.jhep.2023.02.023.
    [12]
    ELKRIEF L, HERNANDEZ-GEA V, SENZOLO M, et al. Portal vein thrombosis: Diagnosis, management, and endpoints for future clinical studies[J]. Lancet Gastroenterol Hepatol, 2024, 9( 9): 859- 883. DOI: 10.1016/S2468-1253(24)00155-9.
    [13]
    LOFFREDO L, PASTORI D, FARCOMENI A, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: A systematic review and meta-analysis[J]. Gastroenterology, 2017, 153( 2): 480- 487. e 1. DOI: 10.1053/j.gastro.2017.04.042.
    [14]
    de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno VII- Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76( 4): 959- 974. DOI: 10.1016/j.jhep.2021.12.022.
    [15]
    PHILIPS CA, RAJESH S, GEORGE T, et al. Early, late, or no shunt embolization in patients with cirrhosis- and portosystemic shunt-related hepatic encephalopathy[J]. Indian J Gastroenterol, 2020, 39( 4): 377- 387. DOI: 10.1007/s12664-020-01042-x.
    [16]
    YI FF, GUO XZ, WANG L, et al. Impact of spontaneous splenorenal shunt on liver volume and long-term survival of liver cirrhosis[J]. J Gastroenterol Hepatol, 2021, 36( 6): 1694- 1702. DOI: 10.1111/jgh.15386.
    [17]
    TALLÓN AGUILAR L, JIMÉNEZ RIERA G, SUÁREZ ARTACHO G, et al. Posttransplantation portal thrombosis secondary to splenorenal shunt persistence[J]. Transplant Proc, 2010, 42( 8): 3169- 3170. DOI: 10.1016/j.transproceed.2010.05.075.
    [18]
    LV Y, BAI W, LI K, et al. Anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis: A prospective observational study[J]. Am J Gastroenterol, 2021, 116( 7): 1447- 1464. DOI: 10.14309/ajg.0000000000001194.
    [19]
    WANG L, GUO XZ, XU XB, et al. Anticoagulation favors Thrombus recanalization and survival in patients with liver cirrhosis and portal vein thrombosis: Results of a meta-analysis[J]. Adv Ther, 2021, 38( 1): 495- 520. DOI: 10.1007/s12325-020-01550-4.
    [20]
    DELGADO MG, SEIJO S, YEPES I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis[J]. Clin Gastroenterol Hepatol, 2012, 10( 7): 776- 783. DOI: 10.1016/j.cgh.2012.01.012.
    [21]
    RAJESH S, PHILIPS CA, AHAMED R, et al. Friend or foe? spontaneous portosystemic shunts in cirrhosis-current understanding and future prospects[J]. Can J Gastroenterol Hepatol, 2021, 2021: 8795115. DOI: 10.1155/2021/8795115.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (365) PDF downloads(37) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return